Australia, 5 April 2012—Avita Medical Ltd. (ASX:AVH;...

Australia, 5 April 2012—Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY), the regenerative medicine
company, has been granted European patent EP1357922B1 “Cell Suspension Preparation
Technique and Use” by the European Patent Office. The patent covers broad claims related to the
preparation of a cell suspension comprised of the patient’s own epithelial cells (autologous
suspension), the therapeutic use of the cell suspension and, importantly, a ‘composition of matter’
claim wherein the actual suspension of autologous cells is covered.
The patented technology is incorporated into the company’s flagship regenerative product, ReCell®
Spray-On Skin®, used in the treatment of chronic and acute wounds and a wide range of
reconstructive and aesthetic procedures.
ReCell is a stand-alone, point-of-care device that allows:
? the harvesting of a small sample of a patient’s own skin and, via a proprietary
enzymatic and mechanical process, the disaggregation of the constituent cells;
? the incorporation of the disaggregated and isolated cells into a suspension consisting
of mature and immature epithelial cells as well as undifferentiated skin cells; and
? the delivery and application of this therapeutic cellular suspension to the patient.
Each of these aspects is covered by the granted patent.
The intellectual property covered under the patent expands and strengthens Avita’s existing
patented technology. The company is continuing to build its intellectual property estate with a
widening range of potential products and applications.
In related news, the US Patent and Trademark Office has awarded Avita the registration for the
trademark “Spray-On Skin®”, US Trademark Registration No 4072126.
“ReCell is a platform technology with immense market potential,” said Avita Medical CEO, Dr William F
Dolphin. “This patent grant further validates Avita’s unique capabilities in harnessing the body’s
ability to heal itself and to regenerate damaged tissue. The patent secures additional protection for
our intellectual property in the rapidly growing field of regenerative medicine. Moreover, securing
the registered trademark ‘Spray-On Skin’ reinforces the company’s global branding as ReCell
increases its presence in worldwide markets.”